Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative ADT plus darolutamide in newly diagnosed hormone-sensitive oligometastatic prostate cancer
ChiCTR2400094395Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Chinese PLA General Hospital. Primary endpoint: Radiographic progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400094395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094395.